$CJMB

CALLAN JMB INC. (CJMB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

CALLAN JMB INC. (CJMB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 Settlement, Waiver and Release Agreement This Settlement, Waiver and Release Agreement (“ Agreement ” or “ Settlement Agreement ”) is made and entered into as of June 5, 2026 (“ Effective Date ”) by and between CALLAN JMB Inc., a Nevada C

Original reporting
Published Jun 11, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CJMB
Neutral
medium confidence
Mentioned
$CJMB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CJMBNeutralLow
01

Why it matters

The settlement specifies $125,000 total severance in three monthly installments, accrued unused vacation payout, and that 212,500 vested stock options remain outstanding/exercisable through their original 10-year term (no shortened post-termination exercise period).

02

Market read

This is a defined executive departure/compensation disclosure; it may move the stock modestly on governance sentiment but lacks new financial or strategic guidance.

03

What to watch

Traders may want to check whether the resignation triggers any additional disclosures (e.g., new officer appointments, board committee changes) in subsequent filings beyond Item 5.02.

Relevance 6/10Novelty 5/10Timing: Filed June 11, 2026 (after-hours/SEC filing window)

Background

The 8-K (Item 5.02) documents termination of an employment agreement and voluntary resignation of an executive who also served on the board, with mutual releases and defined severance/covenant handling.

Company-level read

Ticker impact

$CJMBNeutralMedium confidence
Context

CJMB discloses an executive/board resignation tied to a settlement agreement, including a $125,000 lump-sum severance paid in three installments and continued exercisability of vested options.

Expected impact

Low-to-moderate downside risk from governance/leadership uncertainty; otherwise limited fundamental read-through.

Evidence & confidence

The filing is an Item 5.02 executive departure/compensation arrangement with no stated operational or financial guidance change; the only quantified items are severance and option exercisability mechanics.

Market effects

Minimal—this is company-specific governance/HR news, not a sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Even without operational impact, the continued exercisability of vested options may reduce immediate dilution/overhang concerns versus a scenario where options were shortened or forfeited.

Key entities

  • CALLAN JMB Inc.

    Nevada corporation filing the 8-K; common stock trades on Nasdaq Capital Market under CJMB.

  • Eric Kash

    Executive Vice-President and board member who resigns; receives settlement/severance and vacation payout under the agreement.

Related articles

$CJMBMedAI 8/10

Callan JMB (CJMB) Stock Rallies 50% After Hours: Here's Why it is Trending - Callan Jmb (NASDAQ:CJMB)

Callan JMB Inc. (NASDAQ:CJMB) shares rose about 49.8% to $1.29 after hours after the company said it signed a strategic partnership with Alabama State University to build an integrated pharmaceutical manufacturing ecosystem. Callan will provide logistics and regulatory support and receive 21% of qualifying gross revenue. Management projected annual gross revenues near $500 million, about $105 million for the company. The stock also faces a Nasdaq $1 bid compliance deadline.

$GOOGLMed

Greg Abel Made Major Additions to Alphabet and Delta Last Quarter While Berkshire Bought Back $4.4 Billion of Its Own Stock. Is This a Buying Signal Investors Should Watch?

Berkshire Hathaway, led by Greg Abel, increased investments in Alphabet and Delta Air Lines, and repurchased $4.5 billion of its own stock in Q2. Abel's strategy aligns with Buffett's value-focused approach, with Berkshire holding $359.2 billion in cash and short-term investments post-purchases. Berkshire's buybacks follow a rule where shares are repurchased only when below intrinsic value, with average prices of $476.01 in May and $487.98 in June.

$TMed

AT&T Reshapes International Operations with Mexico Exit

AT&T (T) is selling its wireless business in Mexico and eliminating the role of its global marketing officer, Lori M. Lee, as part of a strategic shift to streamline its international operations. The changes reflect efforts to reconfigure its global strategy and may impact its competitive position in Latin America.

$ASSTHigh

TD Cowen Raises Strive ($ASST) Price Target 27% to $56 on Faster Bitcoin (BTC) Accumulation

TD Cowen raised its price target for Strive, Inc. (ASST) to $56 from $44, citing faster Bitcoin (BTC) accumulation. Strive's BTC holdings grew to 35,595, exceeding estimates. The company issued $630M in preferred shares to fund purchases, maintaining a debt-free balance sheet. Analysts highlight the strategy of financing via preferred equity to grow BTC holdings without issuing common stock.

$MNDYMed

Monday faces senior management exits amid AI restructuring

Israeli software company monday.com (MNDY) expects several senior management departures amid a restructuring and shift to AI-powered work platforms. The company announced a 20% workforce reduction in July, with restructuring costs estimated at $45M-$55M. Q2 2026 revenue was $364.6M, up 22% YoY, with net profit at $3.46M. Shares closed at $90, down 4% on the day and 37% YTD.

$IONQHigh

IonQ’s Bold Cash Raise Rattles Investors and Stock

IonQ's stock fell 13.76% after announcing a $2 billion equity and warrant financing deal. The offering, priced at $40 per unit, includes anti-dilution protections and warrants exercisable at $69.46. Analysts cut price targets, with Rosenblatt reducing its target to $70 and Morgan Stanley to $43, citing dilution concerns. Despite the drop, options data show call buying outpacing puts, and the company is advancing its quantum computing roadmap.